Journal

European Urology

0302-2838 · Elsevier BV

25 verified public works

Browse all journals →

Re: Perioperative Apalutamide In High-risk Localized Prostate Cancer

2026 · 0 citations

Re: Aldo Brassetti, Gabriele Tuderti, Umberto Anceschi, et al. Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.019

2026 · 0 citations

Re: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Five-year Results of the IMPACT Study

2026 · 0 citations

Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial

2026 · 0 citations

Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU–EANM–ESTRO–ESUR–ISUP–SIOG Guidelines on Prostate Cancer—2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.04.013

2026 · 0 citations

Re: A Randomized Controlled Trial Comparing En-bloc Versus Lobe-by-lobe HoLEP: Surgical Efficiency and Early Continence Outcomes

2026 · 0 citations

Re: Sobia Khan, Nathan Papa, Andrew Kneebone, et al. Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium [68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Urol 2026;89:512–20

2026 · 0 citations

Accumulating Evidence Supports NECTIN4 as a Predictive Biomarker for Enfortumab Vedotin: The Compartment Still Matters

2026 · 0 citations

Reply to Paolo Zaurito’s Letter to the Editor re: Robert M. Meier, Nima Aghdam, Alan C. Beckman, et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029

2026 · 0 citations

Reply to Riccardo Lombardo’s Letter to the Editor re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.06.020

2026 · 0 citations

PSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial

2026 · 0 citations

Re: Perioperative Apalutamide in High-risk Localized Prostate Cancer

2026 · 0 citations

Re: Microultrasonography-guided Versus MRI-guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial

2026 · 0 citations

Re: Pierre-Etienne Gabriel, Alec Zhu, Paolo Gontero, Morgan Rouprêt, Evanguelos Xylinas, John P Sfakianos. BCG-unresponsive NMIBC: An Obsolete Definition in a Multimodal and Evolving Therapeutic Landscape. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.028

2026 · 0 citations

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer

2026 · 0 citations

Re: Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9 yr Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial

2026 · 0 citations

Re: Matthew Lee, Michael Lesgart, Connor McPartland, Randall Lee, Daniel D. Eun. Robotic Transvesical Bladder Neck Reconstruction: A Novel Approach to Managing Vesicourethral Anastomotic Stenosis. Eur Urol 2025;88:519–24

2026 · 0 citations

Reply to Pierre-Etienne Gabriel and Evanguelos Xylinas’s Letter to the Editor re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur Urol. 2026;89:93–5

2026 · 0 citations

Re: Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008

2026 · 0 citations

Re: [177Lu]Lu-PSMA-617 in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-naive/sensitive Prostate Cancer (PSMAddition): A Phase 3 Randomised, Controlled Trial

2026 · 0 citations

Stereotactic Body Radiation Therapy in Oligometastatic Castration-resistant Prostate Cancer: Time to Move from Signals to Phase 3 Trial Evidence

2026 · 0 citations

Corrigendum to “Development and Validation of a Multimodal Artificial Intelligence–derived Digital Pathology–based Biomarker Predicting Metastasis Among Patients with Biochemical Recurrence After Radical Prostatectomy in NRG/RTOG Trials” [Eur. Urol. (2025)]

2026 · 0 citations

Re: Alexander Light, Max Peters, Archana Gopalakrishnan, et al. Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.05.007

2026 · 0 citations

Re: Prostate Cancer

2026 · 0 citations

Re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion-targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2026.06.020

2026 · 0 citations